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Bladder exstrophy (BE) is a complex congenital anomaly characterized by a defect in the closure of the lower
abdominal wall and bladder. We aimed to provide an overview of the literature and conduct an epidemiologic
study to describe the prevalence, andmaternal and case characteristics of BE.We used data from22 participating
member programs of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). All
cases were reviewed and classified as isolated, syndrome, and multiple congenital anomalies. We estimated the
total prevalence of BE and calculated the frequency and odds ratios for various maternal and case characteristics.
A total of 546 cases with BE were identified among 26,355,094 births. The total prevalence of BE was 2.07 per
100,000 births (95% CI: 1.90–2.25) and varied between 0.52 and 4.63 among surveillance programs
participating in the study. BEwas nearly twice as common amongmale as among female cases. The proportion of
isolated cases was 71%. Prevalence appeared to increasewith increasing categories of maternal age, particularly
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among isolated cases. The total prevalence of BE showed some variations by geographical region, which is most
likely attributable to differences in registration of cases. The higher total prevalence amongmale cases and older
mothers, especially among isolated cases, warrants further attention.  2011 Wiley Periodicals, Inc.
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INTRODUCTION
Bladder exstrophy (BE) is a rare, com-
plex, and severe congenital anomaly. It is
characterized by a defect in the closure of
the lower abdominal wall and bladder
[ICBDSR, 2009]. The bladder and
related structures (bladder mucosa, ure-
teral orifices, posterior bladder neck, and
urethra) are everted through the ventral
wall of the abdomen between the
umbilicus and symphysis pubis. BE is
often associatedwith structural anomalies
of the pubic bones. Although BE can be
diagnosed with a prenatal ultrasound
[Evangelidis et al., 2004], the diagnosis
is usually made at the time of birth.
In male cases, BE is associated with
epispadias. The phallus is short and broad
with a dorsal chordee. The glans lies
open and flat and the dorsal component
of the foreskin is absent. The urethral
plate extends the length of the phallus
without a roof. The bladder plate and
urethral plate are in continuity with the
verumontanum and the ejaculatory
ducts are visible within the prostatic
urethral plate. The anus is anteriorly
displaced with a normal sphincter
mechanism. The testicles may be
undescended.
In female cases the clitoris is uni-
formly bifid with divergent labia superi-
orly. The open urethral plate is in
continuity with the bladder plate. The
vagina and anus are anteriorly displaced.
In both male and female cases the
pubic symphysis is widely separated.
Divergent rectus muscles remain at-
tached to the pubis [Gearhart, 2002;
Stevenson and Hall, 2006; Ebert et al.,
2009].
In this report we (1) provide an
overview of historical aspects, embryol-
ogy, etiology, clinical characteristics and
genetics, epidemiology, prognosis, and
treatment of BE, and (2) describe the
current epidemiologyof BE using a large
dataset from the International Clearing-
house for Birth Defects Surveillance and
Research (ICBDSR).
BACKGROUND
Historical Aspects
In ancient texts, such as in the cuneiform
tablets of Chaldea dating from 2000 BC,
congenital anomalies were recorded,
including genital malformations. Des-
cription of BE in the cuneiform tables
was suggested [Ballantyne, 1894] but a
definitive description was not corrobo-
rated [Gearhart, 2002]. Several case
reports of BE published in the English
literature dating from the 1800s have
been reviewed [Ballantyne, 1904]. It
has been suggested that BE was first
described in 1595, or perhaps as early as
1583, by the German physician Johann
Schenck von Grafenberg, and later by
John Wood in 1869 [Ludwig et al.,
2009]. TheMuseumVrolik collection at
the University of Amsterdam in The
Netherlands founded by Gerardus
Vrolik (1775–1859) and his sonWillem
Vrolik (1801–1863) includes specimens
with midline anomalies [Oostra et al.,
1998]. Among the specimens there is a
dried pelviswith amarked diastasis of the
pubic rami of a 6-year-old boy, with
an ectopic bladder visible through an
infraumbilical defect of the abdominal
wall, a phenotype characteristic of classic
BE [Oostra et al., 1998; Ludwig et al.,
2009]. The term ‘‘exstrophy’’ is derived
from the Greek word for inside out,
ekstriphein, and was first used by Chauss-
ier in 1780 [Gearhart, 2002; Ro¨sch and
Ebert, 2007].
Embryology
Despite progress in the understanding of
developmental mechanisms, the patho-
genesis of BE remains unclear. During
normal embryological development,
separation of the primitive cloaca into
the urogenital sinus and hindgut occurs
at the same time as maturation of the
anterior abdominal wall [Marshall and
Muecke, 1962]. By the end of the sixth
to seventh week of development, the
infraumbilical mesenchyme migrates
between the ectodermal and endoder-
mal layers of the cloacal membrane,
which is located at the caudal end of the
embryo [Sadler, 2006]. It has been
suggested that failure of mesenchyme
to migrate fully leads to instability of the
cloacal membrane [Mildenberger et al.,
1988; Gearhart, 2002; Stevenson and
Hall, 2006]. Premature rupture of the
membrane before its caudal transloca-
tion leads to a complex of anomalies: the
posterior wall of the bladder is exposed,
as well as other structures derived
from the infraumbilical mesenchyme.
Rupture of the cloacal membrane after
complete separation of the genitouri-
nary and gastrointestinal tracts results
in classical BE [Jones, 2006]. In recent
articles, authors have suggested that
BE is a milder manifestation of a later
event in embryogenesis, in contrast
to the more severe consequences of
cloacal exstrophy resulting from an
earlier event [Martı´nez-Frı´as et al.,
2001; Gearhart, 2002]. A more
detailed description of the normal
development and possible pathogenetic
mechanisms of bladder and cloacal
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exstrophy is given by Feldkamp et al.
[2011] in this issue.
Etiology, Clinical Characteristics,
and Clinical Genetics
BE is the most commonly identified
congenital anomaly in the so-called
epispadias–exstrophy complex. The eti-
ology of BE is not well understood and
there have been suggestions that BE
is part of the spectrum with cloacal
exstrophy [Hendren, 1998; Gearhart,
2002], while others argue that BE is a
distinct defect [Carey, 2001], or a differ-
ent expression of a primary develop-
mental field defect [Martı´nez-Frı´as et al.,
2001]. Outside the genitourinary sys-
tem, association with other anomalies
is relatively uncommon for BE, but
can include omphalocele, anal defects,
neural tube defects, and skeletal defects
[Cadeddu et al., 1997; Martı´nez-Frı´as
et al., 2001; Ebert et al., 2009]. BE is
also part of the Omphalocele-bladder
Exstrophy-Imperforate anus-Spinal de-
fects (OEIS) complex [Carey et al.,
1978; Ka¨lle´n et al., 2000; Carey, 2001].
The rare variant forms of BE include
pseudoexstrophy, duplicate exstrophy,
closed exstrophy, superior vesical fistula
or fissure, inferior vesicle, penopubic
epispadias, and balanic penile epispadias
[Marshall and Muecke, 1962]. In cases
with exstrophy variants, low lying
umbilicus and umbilical and ventral
hernias are frequently described.
Prenatal diagnosis can be made by
ultrasound examinations and the follow-
ing findings could suggest BE: absence of
bladder filling, a low lying umbilicus,
widening of the pubic rami, diminutive
genitalia, and a lower abdominal mass
[Gearhart, 2002; Evangelidis et al.,
2004]. Maternal serum AFP is elevated
due to the exposure of the bladder
mucosa to the amniotic fluid [Stevenson
and Hall, 2006]. Following prenatal
diagnosis, appropriate genetic counsel-
ing and psychological support are im-
portant parts of pregnancy management
[Gearhart, 2002; Ebert et al., 2009].
Whether environmental factors
play a role in the etiology of BE is
unknown. Suggested risk factors [Lud-
wig et al., 2009] include maternal
smoking [Gambhir et al., 2008]; alcohol
consumption [Pinette et al., 1996;
Robin et al., 1996]; exposure to drugs
and medications during pregnancy such
as misoprostol, heparin, valproic acid,
diazepam [Lizcano-Gil et al., 1995;
Orioli and Castilla, 2000; Wakefield
et al., 2002; Keppler-Noreuil et al.,
2007]; rubella infection [Jordan et al.,
1968]; and in vitro fertilization [Wood
et al., 2007]. However, a Hungarian
study did not find an association
between the use of very large doses of
diazepam by pregnant women for sui-
cide attempt and congenital anomalies
[Gidai et al., 2008].
Most cases of BE are sporadic.
However, there is some evidence to
suggest that genetic factors may play a
role. The risk of recurrence of BE in a
given family is approximately 1% [Ives
et al., 1980; Jones, 2006] with recur-
rence of some variant forms ranging
from 0.3% to 2.3% [Shapiro et al., 1984;
Messelink et al., 1994; Reutter et al.,
2003; Boyadjiev et al., 2004]. It has been
suggested that in a few families the
exstrophy–epispadias complex may fol-
low Mendelian inheritance [Reutter
et al., 2003; Ludwig et al., 2009]. Twin
studies have indicated amuch higher rate
of the exstrophy–epispadias complex
among monozygotic twins compared
with dizygotic twins [Reutter et al.,
2007b]. One study reported a one in 70
chance that a parent with BE will have
a child with the same malformation
[Shapiro et al., 1984]. There have been a
few cytogenetic and molecular genetic
studies which indicated that chromo-
some structural anomalies [Boyadjiev
et al., 2004; Thauvin-Robinet et al.,
2004; Ludwig et al., 2009] and some
mutations may be more common
in patients with exstrophy–epispadias
complex [Nye et al., 2000;Reutter et al.,
2006, 2007b], but no specific gene has
been identified to date. Based on previ-
ous studies, it has been suggested that BE
may have a polygenic multifactorial
mode of inheritance [Reutter et al.,
2007a,b], and developmental errors such
as somatic mutations play a role in the
formation of the anomaly [Boyadjiev
et al., 2004].
Descriptive Epidemiology From
Published Literature
BE occurs in approximately 1:30,000–
50,000 live births [Stevenson and Hall,
2006], and is more likely to occur in
males (Table I). There appears to be
geographical variation in the prevalence
of BE. Rickham [1961] reviewed
hospital data in the Liverpool Region
in the United Kingdom, and found a
prevalence of 2.5 and 10.0 per 100,000
live births for years 1941–1953 and
1954–1960, respectively. In an interna-
tional report, the total prevalence was
3.3 per 100,000 births, and ranged from
2.1 per 100,000 births in France to
4.7 per 100,000 births in Denmark
[ICBDMS, 1987]. In a study from Spain
the prevalence of BE was 2.8 per
100,000 births for years 1976–1999
[Martı´nez-Frı´as et al., 2001]. Based on
the most recent data available on the
EUROCAT website, the total preva-
lence of BE and/or epispadias among
European member registries is 5.5 per
100,000 births for years 2000–2009
Outside the genitourinary
system, association with
other anomalies is relatively
uncommon for BE, but can
include omphalocele, anal
defects, neural tube defects, and
skeletal defects. BE is also part
of the Omphalocele-bladder
Exstrophy-Imperforate
anus-Spinal defects (OEIS)
complex.The rare variant forms
of BE include
pseudoexstrophy, duplicate
exstrophy, closed exstrophy,
superior vesical fistula or
fissure, inferior vesicle,
penopubic epispadias, and
balanic penile epispadias.
ARTICLE AMERICAN JOURNAL OF MEDICAL GENETICS PART C (SEMINARS IN MEDICAL GENETICS) 323
[EUROCAT, 2011], with a wide range
of variation in prevalence from 0.0 to
25.6. These differences could be attrib-
utable to variations in sample size,
registration, and inclusion of epispadias
in this category. In theUnited States, one
study found higher prevalence among
newborns in the Northeast, South,
and Midwest region (2.15–2.47 per
100,000) compared with the Western
part of the country (1.37 per 100,000),
with an overall prevalence of 2.15 per
100,000 [Nelson et al., 2005]. A study of
national rates of congenital anomalies
among hospitalized newborns in the
United States reported a prevalence of
3.2 per 100,000 births using hospital
discharge databases with approximately
4 million live births [Bird et al., 2006].
Using data from the New York State
Congenital Malformation Registry,
Caton et al. [2007] described a down-
ward trend by year between 1983 and
1999, with an overall prevalence of
2.1 per 100,000 live births. Among
Native Americans a very high preva-
lence, 8.0 per 100,000 births has been
reported [James et al., 1994].
The male-to-female ratio was 1.5:1
in an international study [ICBDMS,
1987], but much higher male-to-
female ratios of 2.3:1 to 6.0:1 have
been reported by other investigators
[Higgins, 1962; Lattimer and Smith,
1966; Ives et al., 1980; Shapiro et al.,
1984; Grady et al., 1999]. However,
in two other studies no significant
male preponderance was found [Yang
et al., 1994; Nelson et al., 2005].
An earlier study reported that the variant
forms of BE are more common among
females than males in contrast to the
higher prevalence among males seen in
classical BE [Marshall and Muecke,
1962].
In a recent study using data from the
New York State Congenital Malforma-
tions Registry, investigators suggested
summer conception, non-Hispanic
white race/ethnicity, and male infant
sex as possible risk factors for BE [Caton
et al., 2007]. Nelson et al. [2005] found
some significant associations with other
factors: mothers of Black, Hispanic, and
other race/ethnicity had lower risk of
having a child with BE compared with
White mothers; the risk was higher
among mothers with government or
private insurance coverage versus self
pay; and the risk was higher among
mothers with high versus low socioeco-
nomic status. Other associations/poten-
tial risk factors that have been suggested
include young maternal age and high
parity [ICBDMS, 1987]. A lower birth
weight distribution for infants with
BE and multiple congenital anomalies
(MCA) compared with infants with
isolated BE was also described in the
same study [ICBDMS, 1987]. Although,
some studies examined the occurrence
of associated defects among cases
with BE [ICBDMS, 1987; Martı´nez-
Frı´as et al., 2001; Nelson et al., 2005],
there has been no report to date on
demographic or clinical characteristics
among BE cases by isolated and MCA
status.
Prognosis, Treatment, Survival,
Long-Term Health, and
Quality of Life
The prognosis for BE has significantly
improved in recent decades. BE is a life-
threatening condition; therefore, surgi-
cal intervention is required. The com-
plexity of the reconstructive surgery
depends on the extent of the malforma-
tion. The best results with BE have been
achieved with staged reconstruction, a
series of surgeries that take place over a
number of years [Duffy, 1996; Baird
et al., 2007]. Bladder and pelvic closure
are carried out in the newborn period.
Epispadias repair in the male occurs
during the first years of life, and an
operation to correct urine flow and
improve continence is carried out
between ages 3 and 6. Some infants will
be candidates for newborn closure with
epispadias repair at the same time.
Vesicoureteric reflux is very common
among infants after bladder closure [Jeffs,
1987]. With appropriate management
from the newborn period, the child has
a much greater likelihood of having
a functional urinary tract, a much
improved psychosocial development,
and an excellent quality of life
[Ben-Chaim et al., 1996ab; Ebert et al.,
2005, 2008, 2010ab; Catti et al., 2006].
There have been some reports of an
increased risk for malignant tumors of
the urinary tract (bladder and kidney)
among patients with BE between their
third and fifth decades [Kandzari et al.,
1974; Smeulders and Woodhouse,
TABLE I. Prevalence and Sex Ratio of Cases With Bladder Exstrophy in Published Studies
Refs.
Study
period
Number
of cases Population
Prevalence per
100,000 births
Male-to-female
ratio
Rickham [1961] 1941–1953 16 Live births 2.5 Not reported
1954–1960 28 10.0
Caton et al. [2007] 1983–1999 95 Live births 2.1 1.75:1a
ICBDMS [1987] 1967–1985 208 All births 3.3 1.5:1
Martı´nez-Frı´as et al. [2001] 1976–1999 45 All births 2.8 1.32:1
Nelson et al. [2005] 1988–2000 205b Live births 2.15 1:1
Bird et al. [2006] 1997–2001 Not reported Live births 3.2 Not reported
aAmong isolated/sequence BE cases.
bCloacal exstrophy cases may be included.
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2001], suggesting the need for a careful
long-term follow-up of these patients.
METHODS FOR CURRENT
ANALYSIS
We used data from 22 participating
member programs of the ICBDSR.
Surveillance programs were asked to
provide anonymous case data following
a common protocol, with information
on phenotype, genetic testing, and
selected demographic and prenatal
information. The collected data were
reviewed by three authors (CS, MF,
PM), and often required consultation
with participating program directors to
clarify cases for inclusion in the study.
We reviewed diagnosis codes and clinical
descriptions (when available) to classify
BE cases as isolated/sequence, multiple,
or syndrome. In some cases additional
information was requested from mem-
ber programs of ICBDSR to clarify the
diagnosis. BE caseswithout an additional
major defect, or with only related
urogenital malformations were classified
as isolated/sequence. Cases with recog-
nized syndromes and chromosomal syn-
dromes were classified as syndromes.
The remaining cases were classified as
MCA. Cases with BE, for which the
defect was part of OEIS complex, were
considered cloacal exstrophy cases, and
therefore, excluded from this analysis.
We calculated the prevalence for
each birth defects surveillance program
(live birthsþ stillbirthsþ elective termi-
nations of pregnancy for fetal ano-
malies (ETOPFA) cases / live birthsþ
stillbirths) and 95% confidence intervals
(CI) according to the Poisson distribu-
tion. The total prevalencewas computed
by summing up all the cases in each
surveillance program and dividing these
for all the births of the participating
surveillance programs. We also calculat-
ed the frequencyof various maternal and
case characteristics (sex, outcome, birth
weight, gestational age, parity, previous
spontaneous abortions, plurality, mater-
nal age, and maternal education) among
isolated and MCA cases. We estimated
the crude prevalence and prevalence
ratios (PR) for maternal age groups
overall, and stratified by isolated and
MCA status. We used the chi-square test
for trend to analyze temporal trends. To
compare the selected clinical and demo-
graphic characteristics of BE cases with
MCAwith those of isolated BE cases, we
calculated crude and adjusted odds ratios
(OR) and the 95% CIs. Adjustments
were made for tertiles of percentage
of MCA cases to account for possible
differences in the proportion of MCA
cases. Statistical analyses were done with
Stata software, version 10.0 [StataCorp,
2007]. A more detailed description of
the data collection method and variables
for cases and denominator data, as well
as statistical analysis and adjustments is
provided in the introductory paper
[Castilla and Mastroiacovo, 2011].
RESULTS
Among 26,355,094 births we identified
546 cases with BE. Five surveillance
programs (Australia Victoria, France
Central East, Hungary, South America
ECLAMC, and Spain ECEMC) con-
tributed approximately 50% of the cases.
The estimated total prevalence of BE
was 2.07 per 100,000 births (95% CI:
1.90–2.25) and varied between 0.52
and 4.63 among surveillance programs
participating in the study (Table II).
China Beijing and South America
ECLAMC had the lowest prevalence,
while Australia Victoria, Finland, and
Mexico had the highest prevalence with
95% CIs that did not include the overall
prevalence (2.07 per 100,000 births)
for all surveillance programs (Table II
and Fig. 1). Among cases with BE, the
overall percentage of ETOPFAwas 4.2,
or 5.5% (n¼ 23/415) when restricting
only to the 18 surveillance programs that
registered ETOPFA cases.
After excluding nine syndromic
cases (three Edwards syndrome, two
Klinefelter syndrome, two CHARGE
syndrome, and two pentalogy of Can-
trell), Table III shows the distribution of
nonsyndromic cases (n¼ 537) by mater-
nal and case characteristics and by
clinical phenotype (i.e., isolated and
MCA cases). The majority of cases
(71%) had no additional major defects.
Among cases with MCA (n¼ 156) the
most frequent major unrelated malfor-
mations we identified (data not shown)
were the following: 53 omphalocele
(34%), 33 anal defects (21%), 28 neural
tube defects (18%), 26 renal defects
(17%), and 23 cardiac defects (15%).
Among all nonsyndromic cases
with BE, 41 cases had indeterminate
sex, while for 3 cases the sex was not
reported. The male-to-female sex ratio
among cases with known sex was 1.85:1
(P< 0.01). The ratiowas higher (2.09:1)
among isolated cases compared with
cases with MCA (1.26:1), and this
difference was statistically significant
(P¼ 0.02). The majority of nonsyn-
dromic cases were live births (92.0%),
had normal birth weight (83.4% of live
births), and were born at term (77.9%
of live births).
The analysis of the association of the
main maternal and case characteristics of
MCA cases compared with isolated BE
cases (Table IV) suggests that female cases
were more frequent among MCA cases
(aOR¼ 1.56; 95% CI: 1.00–2.44).
Among MCA cases, the frequency of
stillbirths (aOR¼ 24.63; 95%CI: 5.22–
116.20) and ETOPFA (aOR¼ 18.24;
95% CI: 5.74–57.93) was significantly
higher than among isolated cases. Com-
pared with isolated BE cases, cases with
MCA were more likely to be of low
birth weight (<1,500 g: aOR¼ 7.03;
95% CI: 1.37–36.09; 1,500–2,499 g:
aOR¼ 4.34; 95% CI: 2.37–7.95), pre-
term (<32weeks: aOR¼ 4.36; 95%CI:
1.20–15.80; 32–36 weeks: aOR¼
4.00; 95% CI: 2.16–7.42), and have a
mother with less than 9 years of educa-
tion (aOR¼ 2.85; 95% CI: 1.12–7.29).
The prevalence of BE increased
with maternal age, from 1.52 per
100,000 births in age group< 20 years
to 2.69 per 100,000 births in age
group 40 years (data not shown).
Figure 2 shows the PR for various
maternal age groups relative to the
reference age group of <20 years. PRs
showed a significant (P< 0.01) increase
in prevalence by maternal age group,
with the highest prevalence rates in the
age groups of 35–39 years (PR¼ 1.76;
95% CI: 1.16–2.67) and 40 years
(PR¼ 1.76; 95% CI: 0.92–3.39).
When PRs were analyzed by presence
of MCA, the increase in PRs remained
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significant among isolated cases [with
the highest prevalence in the maternal
age group of 35–39 years (PR¼ 2.85;
95% CI: 1.60–5.08)], but not among
MCA cases (Fig. 3).
DISCUSSION
Using the largest international dataset
of BE assembled to date, the total
prevalence is estimated to be 2.07 per
100,000 births (95% CI: 1.90–2.25).
This is in good agreement with pre-
valence estimates previously reported
(Table I); however, those earlier figures
were based on smaller numbers of cases,
and most of them included live births
only. The variation in total prevalence by
surveillance program in our study could
reflect differences in sample size, report-
ing, and registration. The lower preva-
lence of BE in some of the surveillance
programs of ICBDSR (e.g., China Bei-
jing) may be attributable to ETOPFA
cases not being reported in such pro-
grams. It is interesting to note that
several surveillance programs had no
BE cases in the ETOPFA group. This
could be explained by differences in
clinical practice, prenatal diagnosis, and
pregnancy management, or differences
in the frequency of associated major
defects by surveillance program. The
percentage of ETOPFA may also be
affected by the gestational age limit
specified in the abortion law of the
specific country. In a series of cases with
exstrophy–epispadias complex obtained
TABLE II. Total Prevalence of Bladder Exstrophy in 22 Surveillance Programs of the International Clearinghouse for
Birth Defects Surveillance and Research (ICBDSR)
Surveillance program Period Births
Total number
of cases
% of total
cases that were
ETOPFA
Prevalence per
100,000 births 95% CI
Canada Alberta 1980–2005 1,062,483 26 0 2.45 1.60–3.59
USA Utah 1997–2004 380,706 4 0 1.05 0.29–2.69
USA Atlanta 1968–2004 1,283,999 24 0 1.87 1.20–2.78
USA Texas 1996–2002 2,054,788 33 0 1.61 1.11–2.26
Mexico RYVEMCE 1978–2005 1,058,885 34 NP 3.21 2.22–4.49
South America ECLAMC 1982–2006 4,556,173 35 NP 0.77 0.54–1.07
Finland 1993–2004 713,494 33 6.1 4.63 3.18–6.50
Wales 1998–2004 222,309 6 0 2.70 0.99–5.87
Northern Netherlands 1981–2003 369,658 11 0 2.98 1.49–5.32
Germany Saxony–Anhalt 1980–2004 355,184 9 33.3 2.53 1.16–4.81
Slovak Republic 2000–2005 318,257 4 0 1.26 0.34–3.22
Hungary 1980–2005 3,022,194 75 0 2.48 1.95–3.11
France Central East 1979–2004 2,500,214 58 20.7 2.32 1.76–3.00
Italy North East 1981–2004 1,186,497 28 3.6 2.36 1.57–3.41
Italy Emilia Romagna 1982–2004 558,176 18 0 3.22 1.91–5.10
Italy Tuscany 1992–2004 336,744 11 18.2 3.27 1.63–5.84
Italy Campania 1992–2004 643,962 10 0 1.55 0.74–2.86
Italy Sicily 1991–2002 216,257 7 0 3.24 1.30–6.67
Spain ECEMC 1980–2004 2,045,751 52 NR 2.54 1.90–3.33
Israel 1975–2005 151,562 7 14.3 4.62 1.86–9.52
China Beijing 1992–2005 1,927,622 10 NR 0.52 0.25–0.95
Australia Victoria 1983–2004 1,390,179 51 3.9 3.67 2.73–4.82
Total 26,355,094 546 4.2a 2.07 1.90–2.25
ECEMC, Estudio Colaborativo Espan˜ol de Malformaciones Conge´nitas; ECLAMC, Estudio Colaborativo Latino Americano de
Malformaciones Conge´nitas; RYVEMCE, Registro y Vigilancia Epidemiolo´gica de Malformaciones Conge´nitas; ETOPFA, elective
termination of pregnancy for fetal anomaly; CI, confidence interval; NP, not permitted; NR, not reported.
aThe percentage computed on the 18 surveillance programs registering ETOPFA is 5.5% (n¼ 23/415).
Using the largest international
dataset of BE assembled to date,
the total prevalence is estimated
to be 2.07 per 100,000 births
(95% CI: 1.90–2.25). This
is in good agreement with
prevalence estimates previously
reported; however, those earlier
figures were based on smaller
numbers of cases, and most of
them included live births only.
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from the Malformations Surveillance
Program at Brigham and Women’s
Hospital in Boston, USA, 25% of
pregnancies suspected to have this defect
were electively terminated following
prenatal diagnosis [Cromie et al.,
2001]. In a recent study in the United
Kingdom, investigators found that
among women with antenatal suspicion
of bladder or cloacal exstrophy, 31% of
them opted for pregnancy termination
[Goyal et al., 2011]. It can be hypothe-
sized that cases with other associated
major defects are probably terminated
more often than isolated cases with
BE. This latter possibility is consistent
with our findings; the proportion of
ETOPFA was much higher (10.9%)
among MCA cases than among isolated
cases (1.0%).
As suggested by several earlier
studies [Higgins, 1962; Lattimer and
Smith, 1966; Ives et al., 1980; Shapiro
et al., 1984; ICBDMS, 1987; Grady
et al., 1999], we also found a higher
male-to-female ratio (1.85:1), with this
ratio being higher (2.01:1) among
isolated cases with BE. It is important
to point out that not all studies found
male preponderance for BE [Yang
et al., 1994; Nelson et al., 2005],
which could reflect differences in the
classification of cases with BE between
studies. We can conclude that the
predominance of male cases, especially
among isolated cases with BE, is most
likely a real biological phenomenon,
suggesting perhaps an underlying genet-
ic mechanism.
Besides the expected higher rate of
associated genital and renal anomalies
among MCA cases with BE, we ob-
served a higher rate of omphalocele
(34%), anal defects (21%), neural tube
defects (18%), and cardiac defects (15%),
which is consistent with similar findings
by previous investigators [Cadeddu
et al., 1997; Martı´nez-Frı´as et al., 2001;
Ebert et al., 2009]. It is worth noting that
aneuploidy of sex chromosomes has
been reported in association with BE
[Ludwig et al., 2009]. We also found
two cases with Klinefelter syndrome
(47,XXY) in our study.
Compared with isolated cases,
MCA cases had a marginally higher
prevalence of females, whichmay be due
to the increased proportion of indeter-
minate sex reflecting some misclassifica-
tion ofmales as having indeterminate sex
Figure 1. Total prevalence of bladder exstrophy per 100,000 births (bar) and 95%
confidence interval (line) by surveillance program, and overall prevalence (dotted line), in
22 surveillance programs of the International Clearinghouse for BirthDefects Surveillance
and Research (ICBDSR).
The higher prevalence of BE
among infants with MCA
whose mother had less than
9 years of education is a new
finding and may simply reflect
a wide variation in cultures
and populations, or possibly
suggests that factors
associated with education
and socioeconomic status could
be explored as potential risk
factors for BE.
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among MCA cases. Low birth weight
and prematurity are frequently present
among cases of BE with MCA; such
cases are also are more likely to result in
stillbirths and pregnancy terminations
than among isolated cases [Stoll et al.,
2002; Bourke et al., 2005; Fretts, 2005;
Garne et al., 2005; Lewis et al., 2010].
Our findings of higher odds of stillbirths,
ETOPFA, low birth weight, and
preterm birth among MCA cases are
consistent with these earlier observa-
tions. The higher prevalence of BE
among infantswithMCAwhosemother
had less than 9 years of education is a new
finding and may simply reflect a wide
variation in cultures and populations, or
possibly suggests that factors associated
with education and socioeconomic
status could be explored as potential
risk factors for BE. Only one previous
TABLE III. Characteristics of Nonsyndromic Cases With Bladder Exstrophy (BE) Reported by 22 Surveillance Programs
of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR)
All cases (n¼ 537) Cases with isolated BE (n¼ 381) Cases with BE and MCA (n¼ 156)
n (%) n (%) n (%)
Sex
Male 320 59.6 257 67.5 63 40.4
Female 173 32.2 123 32.3 50 32.1
Indeterminate 41 7.6 0 0.0 41 26.3
Missing data 3 0.6 1 0.3 2 1.3
Outcome
Live births 494 92.0 371 97.4 123 78.8
Stillbirths 20 3.7 4 1.0 16 10.3
ETOPFA 21 3.9 4 1.0 17 10.9
Missing data 2 0.4 2 0.5 0 0.0
Birth weight among live births (g)
<1,500 9 1.8 2 0.5 7 5.7
1,500–2,499 59 11.9 28 7.5 31 25.2
>2,500 412 83.4 330 88.9 82 66.7
Missing data 14 2.8 11 3.0 3 2.4
Gestational age among live births (weeks)
<32 12 2.4 4 1.1 8 6.5
32–36 57 11.5 26 7.0 31 25.2
37 385 77.9 304 81.9 81 65.9
Missing data 40 8.1 37 10.0 3 2.4
Parity
0 102 19.0 76 19.9 26 16.7
1 141 26.3 93 24.4 48 30.8
2 104 19.4 67 17.6 37 23.7
Missing data 190 35.4 145 38.1 45 28.8
Previous spontaneous abortions
0 184 34.3 130 34.1 54 34.6
1 35 6.5 20 5.2 15 9.6
Missing data 318 59.2 231 60.6 87 55.8
Plurality
Single 489 91.1 347 91.1 142 91.0
Twin 16 3.0 8 2.1 8 5.1
Triplet 1 0.2 1 0.3 0 0.0
Missing data 31 5.8 25 6.6 6 3.8
Maternal education (years)
<9 57 10.6 32 8.4 25 16.0
9 103 19.2 77 20.2 26 16.7
Missing data 377 70.2 272 71.4 105 67.3
ETOPFA, elective termination of pregnancy for fetal anomaly.
Syndromic cases (n¼ 9) were excluded from analysis.
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study on BE conducted in the US
examined maternal education as a
possible risk factor, but found no
association [Caton et al., 2007]. In
the study by Nelson et al. [2005],
higher socioeconomic status (based
on median ZIP code income) was
associated with a higher prevalence
of BE.
Our analysis by maternal age group
revealed a significantly higher preva-
lence with increasing maternal age. The
stratified analysis by presence of MCA
suggests that this higher prevalence is
observable only among isolated cases
with BE. In a previous study, investi-
gators did not find an association with
maternal age [Caton et al., 2007]. The
reference group for maternal age used in
that study was 20–34 years; the PR was
lower in the age group <20 years, and
higher in the age group 35 years, both
in the crude and adjusted analyses but did
not reach a level of statistical signifi-
cance. In another study [ICBDMS,
1987], investigators found an excess of
cases among youngmothers (<20 years).
In both of these studies, the sample size
was much smaller and may explain the
lack of association with maternal age.
The higher prevalence among older
mothers in our study suggest that some
genetic and/or environmental factors
(i.e., higher in vitro fertilization rate
among older women) may play a role in
the formation of isolated BE [Wood
et al., 2007] and warrants further
investigation.
In a previous international study,
investigators found an increased risk for
mothers with high parity [ICBDMS,
1987]. In our study we could not
TABLE IV. Crude and Adjusted Odds Ratios (OR)With 95% Confidence Intervals (95%CI) for the Association of Various
Characteristics Among Multiple Congenital Anomalies Cases (Cases) Versus Isolated Cases (Controls) of Bladder
Exstrophy Reported by 22 Surveillance Programs of the International Clearinghouse for Birth Defects Surveillance
and Research (ICBDSR)
Crude OR 95% CI Adjusteda OR 95% CI
Sex
Male 1.00 1.00
Female 1.66 1.08 2.55 1.56 1.00 2.44
Outcomeb
Live births 1.00 1.00
Stillbirths 23.21 5.09 105.92 24.63 5.22 116.20
ETOPFA 16.44 5.37 50.29 18.24 5.74 57.93
Birth weight among live births (g)
<1,500 14.08 2.87 69.07 7.03 1.37 36.09
1,500–2,499 4.45 2.53 7.84 4.34 2.37 7.95
2,500 1.00 1.00
Gestational age among live births (weeks)
<32 7.51 2.20 25.55 4.36 1.20 15.80
32–36 4.47 2.52 7.96 4.00 2.16 7.42
37 1.00 1.00
Parity
0 1.00 1.00
1 1.75 0.94 3.27 1.30 0.66 2.54
2 1.78 0.93 3.41 1.61 0.80 3.25
Previous spontaneous abortions
0 1.00 1.00
1 1.65 0.78 3.51 1.83 0.80 4.20
Plurality
Single 1.00 1.00
Twin 2.44 0.90 6.64 2.35 0.81 6.84
Maternal education (years)
<9 2.46 1.06 5.74 2.85 1.12 7.29
9 1.00 1.00
ETOPFA, elective termination of pregnancy for fetal anomalies.
Surveillance programs with more than 20% missing data were excluded from the analysis.
aAdjustments were made for tertiles of percentage of MCA cases in each program.
bOR computed only for the 18 programs reporting ETOPFA.
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confirm this finding. When we com-
pared MCA cases with isolated cases
with BE, the adjusted OR was higher
among multiparous compared with nul-
liparous mothers, but the CI included
1.0. This nonsignificant association with
parity could reflect a small sample size
and/or bias because of the high propor-
tion of missing data (35%) for this
variable.
The strengths of our study include
the largest sample of cases of BE
examined to date in one study, a diverse
population from 22 different surveil-
lance programs representing several
countries in the world, and analysis of
prevalence by various maternal and case
characteristics. A further strength of the
study is the centralized and standardized
classification of cases with associated
anomalies by experts in the field. It is
important to recognize the need for
careful review and assessment of cases
with BE in future studies instead of
analyzing the data based only on con-
genital anomaly codes, which may
include cases with cloacal exstrophy,
and may consequently yield higher
prevalence estimates. One of the limi-
tations of the present study is the large
proportion of missing data for some of
the variables such as previous spontane-
ous abortion and maternal education. In
addition, we were not able to analyze
some of the factors that have been
suggested to be associated with BE in
previous studies such as race/ethnicity,
season of birth, socioeconomic status,
and presence and type of medical
insurance.
CONCLUSIONS
BE is a very rare congenital anomaly
with an occurrence of approximately 1
in 50,000 births. Much of the geo-
graphical variation in prevalence is most
likely attributable to differences in
registration of cases. The higher pre-
valence among male cases and older
mothers, especially among isolated cases
are important factors to note for clini-
cians when assessing risk, and to include
in future epidemiologic studies.
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